With HELIOS-3 Phase 3 trial for AXPAXLI now on its way, we could be looking at a major winner in the future. This treatment could completely change how diabetic retinal diseases are managed if it proves successful. That's huge! I know there's a big... — read more
What's up?
OCUL isn't performing as it used to. Is there something going on that the general public isn't aware of?
Bad...
Best avoid this stock like the plague... it didn't amount to nothing in the end and it's a waste of time to pursue it.
Tremendous long-term potential
Ocular Therapeutix is a great long-term investment right now. The company has enormous long-term potential thanks to several candidates that are bound to take its profit in the right direction. Considering that it went down from its 52-week high of... — read more